Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 78

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 78
---
 Mr. Macpherson holds a BA in Economics from Gettysburg College.

67

Key
Consultants

On
March 8, 2024, and subsequently amended on January 24, 2025, we entered into an Amended and Restated Consulting Agreement with Angel
Pharmaceutical Consulting & Technologies Ltd., an Israeli consulting firm (“APCT”). All services provided to our company
by APCT (which began in October 2023) are provided directly by Dr. Itzchak Angel, who shall be our Chief Scientific Advisor. Dr. Angel
has over 30 years of experience in the pharmaceutical industry, guiding strategic drug and business development initiatives in both large
and emerging companies.

Dr.
Angel has served as Head of Pharmacology of Synthelabo (Paris, France, now Sanofi) for numerous years, where he was instrumental in the
development and bringing into the market of several drugs such as Xatral (Alfuzosin), Ambien (Zolpidem) and Mizollen (Mizolastine). He
formerly served as President and Chief Executive Officer of stem-cell company Accellta (Haifa, Israel) and Vice President for Research
and Development at Proteologics Ltd, and at D-Pharm Biopharmaceuticals (Rehovot, Israel) where he developed several neurology compounds
(stroke, Alzheimer’s and Parkinson’s Disease) into advanced clinical development and was involved in submitting numerous
INDs of drugs under development. Dr. Angel is the author of more than 100 book chapters, papers, and abstracts as well as the named inventor
of a number of pharmaceutical patents. Dr. Angel received his B.S. and M.Sc. in Biology from Tel-Aviv University, Israel, cum laude in
1979, and received Ph.D. cum laude from the Hamburg University, Germany in 1982.

As
part of his consulting services, Dr. Angel shall assist our company with (i) pharmaceutical regulatory affairs, toxicology, drug research
and pre-clinical and clinical testing, (ii) outsourcing and helping our company in managing third party vendors and (iii) working with
our company in our interactions with regulatory bodies.

Board
Composition

Our
business and affairs are managed under the direction of our board of directors, which currently consists of five members. The number
of directors is determined by our board of directors, subject to the terms of our amended and restated